	US 12,274,702 B2
	Nasal compositions comprising alcaftadine
Akhilesh Sharma, Mumbai (IN); Babasaheb Aware, Taluka and District Beed (IN); Viraj Shah, Dist-Dhule (IN); and Amol Aiwale, Pandharpur (IN)
Assigned to ALKEM LABORATORIES LIMITED, Mumbai (IN)
Filed by ALKEM LABORATORIES LIMITED, Mumbai (IN)
Filed on Nov. 11, 2024, as Appl. No. 18/943,210.
Application 18/943,210 is a continuation of application No. 18/549,916, previously published as PCT/IB2021/055221, filed on Jun. 14, 2021.
Claims priority of application No. 202121015680 (IN), filed on Apr. 1, 2021.
Prior Publication US 2025/0064827 A1, Feb. 27, 2025
Int. Cl. A61K 31/55 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/38 (2006.01)

CPC A61K 31/55 (2013.01) [A61K 9/0043 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/186 (2013.01); A61K 47/38 (2013.01)]

24 Claims

1. A method of treating seasonal allergic rhinitis in a human patient in need thereof comprising nasally administering once daily to the patient an effective amount of an aqueous pharmaceutical composition comprising 0.125% to 0.75% w/w alcaftadine or a pharmaceutically acceptable salt thereof and a mucoadhesive agent.